CorMedix Inc. (NASDAQ: CRMD) is a Healthcare company (Biotechnology) with a market capitalization of $371M. The Maz Rating grades it against the other companies in its sector.
CorMedix Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.67, CorMedix Inc. trades at 5.9x trailing earnings, 0.9x sales and 0.8x book value, with an EV/EBITDA of 0.9. Over the last twelve months it generated about $410M of revenue and $63M of net income. It runs a gross margin of 77.5%, an operating margin of 38.6% and a net margin of 15.5%. It shows return on equity of 14.5%, return on invested capital of 10.6% and a free cash flow yield of 82.6%. On the balance sheet: a debt-to-equity ratio of 0.31 and a current ratio of 2.43. Over the past 52 weeks the share price ranged from $4.63 to $13.02, with a beta of 1.48.
CorMedix Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, CorMedix Inc. (CRMD) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 25.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 61.7% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 25.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 61.6% / 33% · Receivables / Mkt Cap (36m) 13.3% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 25.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 61.6% / 33.33% · Receivables / Mkt Cap (24m) 13.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 16.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 27.1% / 33.33% · Receivables / Avg Assets (4Q) 16.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 15.8% / 33.33% · (Cash+ST Inv) / Total Assets 38.7% / 33.33% · (Cash+Recv) / Total Assets 47.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, CorMedix Inc. (CRMD) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
No. CorMedix Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
CorMedix Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.